Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2018 | 12 | 0.690 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2019 | 4 | 0.600 |
Why?
|
| Hand-Foot Syndrome | 1 | 2018 | 2 | 0.590 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 11 | 0.590 |
Why?
|
| Pancreatitis | 1 | 2019 | 36 | 0.580 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 44 | 0.550 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2018 | 108 | 0.520 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 548 | 0.380 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 29 | 0.370 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 39 | 0.290 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 42 | 0.280 |
Why?
|
| Mediastinal Neoplasms | 2 | 2018 | 11 | 0.280 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2018 | 16 | 0.280 |
Why?
|
| Recurrence | 2 | 2019 | 326 | 0.270 |
Why?
|
| Middle Aged | 6 | 2023 | 7414 | 0.200 |
Why?
|
| Humans | 14 | 2023 | 28851 | 0.190 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 84 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 113 | 0.170 |
Why?
|
| Female | 9 | 2023 | 15624 | 0.170 |
Why?
|
| Treatment Outcome | 4 | 2018 | 2426 | 0.150 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2018 | 2 | 0.150 |
Why?
|
| Male | 9 | 2023 | 13921 | 0.150 |
Why?
|
| Adult | 6 | 2023 | 8024 | 0.150 |
Why?
|
| Acute Disease | 1 | 2019 | 155 | 0.140 |
Why?
|
| Sarcoma, Myeloid | 1 | 2018 | 7 | 0.140 |
Why?
|
| Smoothened Receptor | 1 | 2018 | 9 | 0.140 |
Why?
|
| Biphenyl Compounds | 1 | 2018 | 22 | 0.140 |
Why?
|
| Anilides | 1 | 2018 | 24 | 0.140 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2018 | 15 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 164 | 0.140 |
Why?
|
| Neck | 1 | 2018 | 26 | 0.140 |
Why?
|
| Lymphoma, Follicular | 1 | 2018 | 13 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 151 | 0.130 |
Why?
|
| Ploidies | 1 | 2017 | 6 | 0.130 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2017 | 3 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2018 | 103 | 0.130 |
Why?
|
| Chromosome Aberrations | 1 | 2017 | 37 | 0.130 |
Why?
|
| Antibodies | 1 | 2018 | 125 | 0.130 |
Why?
|
| Pyridines | 1 | 2018 | 108 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 105 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 285 | 0.130 |
Why?
|
| Disease Progression | 1 | 2018 | 477 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 147 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 336 | 0.120 |
Why?
|
| Young Adult | 2 | 2023 | 2833 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 481 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 360 | 0.110 |
Why?
|
| Obesity | 1 | 2018 | 699 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 686 | 0.090 |
Why?
|
| Aged | 3 | 2023 | 5598 | 0.060 |
Why?
|
| SEER Program | 1 | 2023 | 47 | 0.050 |
Why?
|
| Adolescent | 2 | 2023 | 3193 | 0.050 |
Why?
|
| Standard of Care | 1 | 2022 | 12 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 42 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 14 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 75 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 32 | 0.050 |
Why?
|
| Rituximab | 1 | 2022 | 64 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 44 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2022 | 63 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 23 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 84 | 0.050 |
Why?
|
| Cisplatin | 1 | 2022 | 186 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 222 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2018 | 22 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 25 | 0.040 |
Why?
|
| Leptin | 1 | 2018 | 67 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 110 | 0.040 |
Why?
|
| Species Specificity | 1 | 2018 | 194 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 115 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 433 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 194 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2018 | 83 | 0.030 |
Why?
|
| Platelet Count | 1 | 2018 | 111 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 208 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2018 | 118 | 0.030 |
Why?
|
| Body Weight | 1 | 2018 | 250 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 2065 | 0.030 |
Why?
|
| Age of Onset | 1 | 2017 | 72 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 612 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2018 | 163 | 0.030 |
Why?
|
| Diet | 1 | 2018 | 241 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 824 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 811 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 1350 | 0.030 |
Why?
|
| Animals | 2 | 2018 | 10684 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 1653 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 1469 | 0.020 |
Why?
|
| Neoplasms | 1 | 2018 | 874 | 0.020 |
Why?
|